Javascript must be enabled to continue!
Abstract 1890: Calcitonin receptor is required for T-antigen-induced prostate carcinogenesis
View through CrossRef
Abstract
Calcitonin & calcitonin receptor axis (CT-CTR) expression is increased in prostate cancer & its levels positively correlate with Gleason grade of prostate cancer. Moreover, activation of CT-CTR autocrine axis promotes several processes with tumor progression such as, tumor growth, invasion, angiogenesis, chemoresistance & metastasis. However, the role of CT-CTR axis in carcinogenesis process has not been investigated. To examine the role of CT-CTR axis in prostate carcinogenesis we examined the impact of CTR deficiency on T-antigen-induced prostate tumorigeneses in transgenic mice. We achieved this by cross-breading CTR-knockout mice with LPB-Tag mice (the transgenic mice that uses long Probasin promotor for prostate-specific expression of Tag T-antigen). The cross-breeding of these two transgenic mice yielded four different groups of mice with the following genotypes 1. Control (which lacked both transgenes), 2. CTRKO (only CTRKO transgene), 3. LPB-Tag (contained LPB-Tag transgene), & 4. CTRKO-LPB-Tag (expressed Both CTRKO & LPB-Tag transgenes). The growth of these mice were monitored until they reached the age of 90 days. The mice were sacrificed, the prostates were collected, fixed & evaluated by histology & immunohistochemistry. The results suggest that the mice of all groups developed normally with the exception of LPB-Tag group which displayed slower growth & the presence of prostatic tumors at the time of necropsy. Although all LPB-Tag mice displayed all prostate tumors, as expected wild type & CTRKO mice did not display change in the size or mass of prostates. Subsequently, H&E histology as well as Ki67 staining confirmed that all LPB-Tag mice displayed well-developed prostatic adenocarcinoma, all CTRKO-LPB-Tag displayed no presence of tumor with the exception of occasional presence of HGPIN. Since our earlier studies have shown that CTR induced epithelial-to-mesenchymal transition (EMT) in prostate cancer cell lines, we also examined the expression of two epithelial markers, ZO-1 & E-cadherin, & two mesenchymal markers, fibronectin & vimentin. The results suggest that prostates of the three groups ( WT, CTRKO, LPB-Tag-CTRKO) displayed higher epithelial markers expression with a remarkably lower expression of mesenchymal markers when compared with those of LPB-Tag group. This was further substantiated by the expression of EMT markers such as snail & N-cadherin. In conclusion, this study shows that the CTR deficiency inhibits prostate carcinogenesis in LPB-Tag mice without reducing T-antigen expression or causing any other apparent harmful side effects. This work was supported by NIH grant CA096534.
Citation Format: Afaf Aldahish, Arvind Thakkar, Girish V. Shah. Calcitonin receptor is required for T-antigen-induced prostate carcinogenesis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1890.
American Association for Cancer Research (AACR)
Title: Abstract 1890: Calcitonin receptor is required for T-antigen-induced prostate carcinogenesis
Description:
Abstract
Calcitonin & calcitonin receptor axis (CT-CTR) expression is increased in prostate cancer & its levels positively correlate with Gleason grade of prostate cancer.
Moreover, activation of CT-CTR autocrine axis promotes several processes with tumor progression such as, tumor growth, invasion, angiogenesis, chemoresistance & metastasis.
However, the role of CT-CTR axis in carcinogenesis process has not been investigated.
To examine the role of CT-CTR axis in prostate carcinogenesis we examined the impact of CTR deficiency on T-antigen-induced prostate tumorigeneses in transgenic mice.
We achieved this by cross-breading CTR-knockout mice with LPB-Tag mice (the transgenic mice that uses long Probasin promotor for prostate-specific expression of Tag T-antigen).
The cross-breeding of these two transgenic mice yielded four different groups of mice with the following genotypes 1.
Control (which lacked both transgenes), 2.
CTRKO (only CTRKO transgene), 3.
LPB-Tag (contained LPB-Tag transgene), & 4.
CTRKO-LPB-Tag (expressed Both CTRKO & LPB-Tag transgenes).
The growth of these mice were monitored until they reached the age of 90 days.
The mice were sacrificed, the prostates were collected, fixed & evaluated by histology & immunohistochemistry.
The results suggest that the mice of all groups developed normally with the exception of LPB-Tag group which displayed slower growth & the presence of prostatic tumors at the time of necropsy.
Although all LPB-Tag mice displayed all prostate tumors, as expected wild type & CTRKO mice did not display change in the size or mass of prostates.
Subsequently, H&E histology as well as Ki67 staining confirmed that all LPB-Tag mice displayed well-developed prostatic adenocarcinoma, all CTRKO-LPB-Tag displayed no presence of tumor with the exception of occasional presence of HGPIN.
Since our earlier studies have shown that CTR induced epithelial-to-mesenchymal transition (EMT) in prostate cancer cell lines, we also examined the expression of two epithelial markers, ZO-1 & E-cadherin, & two mesenchymal markers, fibronectin & vimentin.
The results suggest that prostates of the three groups ( WT, CTRKO, LPB-Tag-CTRKO) displayed higher epithelial markers expression with a remarkably lower expression of mesenchymal markers when compared with those of LPB-Tag group.
This was further substantiated by the expression of EMT markers such as snail & N-cadherin.
In conclusion, this study shows that the CTR deficiency inhibits prostate carcinogenesis in LPB-Tag mice without reducing T-antigen expression or causing any other apparent harmful side effects.
This work was supported by NIH grant CA096534.
Citation Format: Afaf Aldahish, Arvind Thakkar, Girish V.
Shah.
Calcitonin receptor is required for T-antigen-induced prostate carcinogenesis [abstract].
In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA.
Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1890.
Related Results
Diagnostic Accuracy of Prostatic Specific Antigen Densityin Different Prostatic Disorders
Diagnostic Accuracy of Prostatic Specific Antigen Densityin Different Prostatic Disorders
Objective: To determine the diagnostic accuracy of PSA density in Prostate Cancer, Benign Prostatic Hyperplasia (BPH) and Prostatitis, taking biopsy as the gold standard.
Stu...
Importance of gender-specific calcitonin thresholds in screening for occult sporadic medullary thyroid cancer
Importance of gender-specific calcitonin thresholds in screening for occult sporadic medullary thyroid cancer
Men and women differ in thyroidal C-cell mass and calcitonin secretion. This difference may have implications for the definition of calcitonin thresholds to distinguish sporadic C-...
Study on Early Prostate Cancer Antigen (EPCA) and existent risk factors of prostate cancer, Sudan: A case-control study
Study on Early Prostate Cancer Antigen (EPCA) and existent risk factors of prostate cancer, Sudan: A case-control study
Background: Early prostate cancer antigen (EPCA), a nuclear matrix protein, has recently been recommended as a hopeful biomarker for early prostate carcinogenesis. Objectives: To e...
Holmium laser enucleation of the prostate versus bipolar transurethral enucleation of the prostate in management of benign prostatic hyperplasia: A randomized controlled trial
Holmium laser enucleation of the prostate versus bipolar transurethral enucleation of the prostate in management of benign prostatic hyperplasia: A randomized controlled trial
Objective
To evaluate the safety, efficacy and cost‐effectiveness of holmium enucleation of the prostate and bipolar transurethral enucleation of the prostate.
...
Abstract 5758: Deletions of olfactomedin 4 gene is associated with progression of prostate cancer
Abstract 5758: Deletions of olfactomedin 4 gene is associated with progression of prostate cancer
Abstract
The human olfactomedin 4 gene (OLFM4) encodes an olfactomedin-related glycoprotein, which our group first cloned and characterized in myeloid cells and mapp...
Characterization of the calcitonin/CGRP gene in Williams syndrome
Characterization of the calcitonin/CGRP gene in Williams syndrome
AbstractWe have investigated the possibility of mutations in the calcitonin/calcitonin gene related peptide (CGRP) gene in children with Williams syndrome. Involvement of the calci...
Abstract 1568: The role of CCL2 CCL17 CCL22-CCR4 axis in prostate cancer metastasis
Abstract 1568: The role of CCL2 CCL17 CCL22-CCR4 axis in prostate cancer metastasis
Abstract
BACKGROUND: Multiple steps and factors are involved in prostate carcinogenesis and tumor progression. The early studies have found that tumor-associated mac...
Abstract 4602: Clinicopathological and genetic features of prostate cancer in Algerian patients: First report
Abstract 4602: Clinicopathological and genetic features of prostate cancer in Algerian patients: First report
Abstract
Background: Prostate cancer is the second most frequent malignancy (after lung cancer) in men worldwide. It is the third most common cancer in men in Algeri...

